1,3,5 and 1,2,4-triazines as Potent Scaffolds for Molecules Potentially Attenuating Breast Cancer Cell Lines

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11160%2F22%3A10458811" target="_blank" >RIV/00216208:11160/22:10458811 - isvavai.cz</a>

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=ulkjwIeHJF" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=ulkjwIeHJF</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2174/1385272827666230215141854" target="_blank" >10.2174/1385272827666230215141854</a>

Jazyk výsledku

angličtina

Název v původním jazyce

1,3,5 and 1,2,4-triazines as Potent Scaffolds for Molecules Potentially Attenuating Breast Cancer Cell Lines

Popis výsledku v původním jazyce

Breast cancer was diagnosed in around 2.3 million women in 2020. Owing to the alarming rise in the incidence of breast cancer, newer small molecules with targeted therapy are the need of the hour. A plethora of small molecules has been approved by the USFDA in the past few years. Triazine is a six-membered aromatic nitrogen heterocyclic molecule that was investigated for its various types of biological activities specially anticancer activity. Triazines are studied in many derivatives having remarkable anti-tumor activity as reported in this literature. Triazines are reported to possess a variety of biological activities and have been widely investigated as a scaffold for developing newer anti-tumor agents with an ability to inhibit various types of cancers, including breast cancers. Triazine derivatives show anticancer activity by inhibiting various targets like mTOR- kinase, PIP3-kinase, epidermal growth factor, etc. A limited number of triazine derivatives have also been clinically used for the treatment of breast cancer. A detailed study of the literature available on various derivatives of triazines with primary applicability as cytotoxic to breast cancer cell was carried out and is presented in this review. A total of 66 structurally diverse triazines have been reported in this review along with the structural features responsible for activity against various breast cancer cell lines. The primary amino residues to which the triazine based molecules bind in the estrogen receptor alpha and epidermal growth factor receptor 2, as found in various docking studies have also been detailed in the review.

Název v anglickém jazyce

1,3,5 and 1,2,4-triazines as Potent Scaffolds for Molecules Potentially Attenuating Breast Cancer Cell Lines

Popis výsledku anglicky

Breast cancer was diagnosed in around 2.3 million women in 2020. Owing to the alarming rise in the incidence of breast cancer, newer small molecules with targeted therapy are the need of the hour. A plethora of small molecules has been approved by the USFDA in the past few years. Triazine is a six-membered aromatic nitrogen heterocyclic molecule that was investigated for its various types of biological activities specially anticancer activity. Triazines are studied in many derivatives having remarkable anti-tumor activity as reported in this literature. Triazines are reported to possess a variety of biological activities and have been widely investigated as a scaffold for developing newer anti-tumor agents with an ability to inhibit various types of cancers, including breast cancers. Triazine derivatives show anticancer activity by inhibiting various targets like mTOR- kinase, PIP3-kinase, epidermal growth factor, etc. A limited number of triazine derivatives have also been clinically used for the treatment of breast cancer. A detailed study of the literature available on various derivatives of triazines with primary applicability as cytotoxic to breast cancer cell was carried out and is presented in this review. A total of 66 structurally diverse triazines have been reported in this review along with the structural features responsible for activity against various breast cancer cell lines. The primary amino residues to which the triazine based molecules bind in the estrogen receptor alpha and epidermal growth factor receptor 2, as found in various docking studies have also been detailed in the review.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30104 - Pharmacology and pharmacy

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Current Organic Chemistry

ISSN

1385-2728

e-ISSN

1875-5348

Svazek periodika

26

Číslo periodika v rámci svazku

24

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

15

Strana od-do

2188-2202

Kód UT WoS článku

000958785800003

EID výsledku v databázi Scopus

—